Summit Therapeutics SMMT Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's cash provided by (used in) operating activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
- Summit Therapeutics (SMMT) reported cash provided by (used in) operating activity, including discontinued operation of -$122.29M in Q1 2026.
- How has Summit Therapeutics's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
- Summit Therapeutics's cash provided by (used in) operating activity, including discontinued operation decreased by 99.9% year-over-year, from -$61.17M to -$122.29M.
- What is the long-term trend for Summit Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
- Over 3 years (2021 to 2025), Summit Therapeutics's cash provided by (used in) operating activity, including discontinued operation has grown at a 64.5% compound annual growth rate (CAGR), from -$72.59M to -$322.93M.